281 related articles for article (PubMed ID: 31978211)
81. Therapeutic effects of an anti-Myc drug on mouse pancreatic cancer.
Stellas D; Szabolcs M; Koul S; Li Z; Polyzos A; Anagnostopoulos C; Cournia Z; Tamvakopoulos C; Klinakis A; Efstratiadis A
J Natl Cancer Inst; 2014 Dec; 106(12):. PubMed ID: 25306215
[TBL] [Abstract][Full Text] [Related]
82. Biology of the lymphomas: cytogenetics, molecular biology, and virology.
Ambinder RF; Griffin CA
Curr Opin Oncol; 1991 Oct; 3(5):806-12. PubMed ID: 1661167
[TBL] [Abstract][Full Text] [Related]
83. Shikonin exerts antitumor activity in Burkitt's lymphoma by inhibiting C-MYC and PI3K/AKT/mTOR pathway and acts synergistically with doxorubicin.
Ni F; Huang X; Chen Z; Qian W; Tong X
Sci Rep; 2018 Feb; 8(1):3317. PubMed ID: 29463831
[TBL] [Abstract][Full Text] [Related]
84. CDK4 deficiency promotes genomic instability and enhances Myc-driven lymphomagenesis.
Lu Y; Wu Y; Feng X; Shen R; Wang JH; Fallahi M; Li W; Yang C; Hankey W; Zhao W; Ganju RK; Li MO; Cleveland JL; Zou X
J Clin Invest; 2014 Apr; 124(4):1672-84. PubMed ID: 24614102
[TBL] [Abstract][Full Text] [Related]
85. Carnitine-acyltransferase system inhibition, cancer cell death, and prevention of myc-induced lymphomagenesis.
Pacilli A; Calienni M; Margarucci S; D'Apolito M; Petillo O; Rocchi L; Pasquinelli G; Nicolai R; Koverech A; Calvani M; Peluso G; Montanaro L
J Natl Cancer Inst; 2013 Apr; 105(7):489-98. PubMed ID: 23486551
[TBL] [Abstract][Full Text] [Related]
86. Disruption of the Myc-PDE4B regulatory circuitry impairs B-cell lymphoma survival.
Nam J; Kim DU; Kim E; Kwak B; Ko MJ; Oh AY; Park BJ; Kim YW; Kim A; Sun H; Jung Y; Lee JH; Shin HJ; Park I; Song DK; Jeong JY; Lee YH; Kim SW
Leukemia; 2019 Dec; 33(12):2912-2923. PubMed ID: 31138843
[TBL] [Abstract][Full Text] [Related]
87. Distinct roles for PARP-1 and PARP-2 in c-Myc-driven B-cell lymphoma in mice.
Galindo-Campos MA; Lutfi N; Bonnin S; Martínez C; Velasco-Hernandez T; García-Hernández V; Martín-Caballero J; Ampurdanés C; Gimeno R; Colomo L; Roué G; Guilbaud G; Dantzer F; Navarro P; Murga M; Fernández-Capetillo O; Bigas A; Menéndez P; Sale JE; Yélamos J
Blood; 2022 Jan; 139(2):228-239. PubMed ID: 34359075
[TBL] [Abstract][Full Text] [Related]
88. MYC needs MNT to drive B cells over the edge.
Janz S
Blood; 2020 Mar; 135(13):977-978. PubMed ID: 32219348
[TBL] [Abstract][Full Text] [Related]
89. A c-Myc and surface CD19 signaling amplification loop promotes B cell lymphoma development and progression in mice.
Poe JC; Minard-Colin V; Kountikov EI; Haas KM; Tedder TF
J Immunol; 2012 Sep; 189(5):2318-25. PubMed ID: 22826319
[TBL] [Abstract][Full Text] [Related]
90. Endogenous Myc maintains the tumor microenvironment.
Sodir NM; Swigart LB; Karnezis AN; Hanahan D; Evan GI; Soucek L
Genes Dev; 2011 May; 25(9):907-16. PubMed ID: 21478273
[TBL] [Abstract][Full Text] [Related]
91. The class-specific BCR tonic signal modulates lymphomagenesis in a c-myc deregulation transgenic model.
Amin R; Marfak A; Pangault C; Oblet C; Chanut A; Tarte K; Denizot Y; Cogné M
Oncotarget; 2014 Oct; 5(19):8995-9006. PubMed ID: 25229630
[TBL] [Abstract][Full Text] [Related]
92. Unexpected suppression of tumorigenesis by c-MYC via TFAP4-dependent restriction of stemness in B lymphocytes.
Tonc E; Takeuchi Y; Chou C; Xia Y; Holmgren M; Fujii C; Raju S; Chang GS; Iwamoto M; Egawa T
Blood; 2021 Dec; 138(24):2526-2538. PubMed ID: 34283887
[TBL] [Abstract][Full Text] [Related]
93. MYC functions as a switch for natural killer cell-mediated immune surveillance of lymphoid malignancies.
Swaminathan S; Hansen AS; Heftdal LD; Dhanasekaran R; Deutzmann A; Fernandez WDM; Liefwalker DF; Horton C; Mosley A; Liebersbach M; Maecker HT; Felsher DW
Nat Commun; 2020 Jun; 11(1):2860. PubMed ID: 32503978
[TBL] [Abstract][Full Text] [Related]
94. Repression of LKB1 by
Izreig S; Gariepy A; Kaymak I; Bridges HR; Donayo AO; Bridon G; DeCamp LM; Kitchen-Goosen SM; Avizonis D; Sheldon RD; Laister RC; Minden MD; Johnson NA; Duchaine TF; Rudoltz MS; Yoo S; Pollak MN; Williams KS; Jones RG
Cell Rep Med; 2020 May; 1(2):100014. PubMed ID: 32478334
[TBL] [Abstract][Full Text] [Related]
95. Insights about MYC and Apoptosis in B-Lymphomagenesis: An Update from Murine Models.
Vecchio E; Fiume G; Correnti S; Romano S; Iaccino E; Mimmi S; Maisano D; Nisticò N; Quinto I
Int J Mol Sci; 2020 Jun; 21(12):. PubMed ID: 32549409
[TBL] [Abstract][Full Text] [Related]
96. Inhibitor of MYC identified in a Kröhnke pyridine library.
Hart JR; Garner AL; Yu J; Ito Y; Sun M; Ueno L; Rhee JK; Baksh MM; Stefan E; Hartl M; Bister K; Vogt PK; Janda KD
Proc Natl Acad Sci U S A; 2014 Aug; 111(34):12556-61. PubMed ID: 25114221
[TBL] [Abstract][Full Text] [Related]
97. TC-PTP is required for the maintenance of MYC-driven B-cell lymphomas.
Young RM; Polsky A; Refaeli Y
Blood; 2009 Dec; 114(24):5016-23. PubMed ID: 19755676
[TBL] [Abstract][Full Text] [Related]
98. Protein phosphatase 2A activation as a therapeutic strategy for managing MYC-driven cancers.
Farrington CC; Yuan E; Mazhar S; Izadmehr S; Hurst L; Allen-Petersen BL; Janghorban M; Chung E; Wolczanski G; Galsky M; Sears R; Sangodkar J; Narla G
J Biol Chem; 2020 Jan; 295(3):757-770. PubMed ID: 31822503
[TBL] [Abstract][Full Text] [Related]
99. MYC Oncogene: A Druggable Target for Treating Cancers with Natural Products.
Chan KI; Zhang S; Li G; Xu Y; Cui L; Wang Y; Su H; Tan W; Zhong Z
Aging Dis; 2024 Apr; 15(2):640-697. PubMed ID: 37450923
[TBL] [Abstract][Full Text] [Related]
100. Caspase-resistant ROCK1 expression prolongs survival of Eµ-Myc B cell lymphoma mice.
Mardilovich K; Naylor G; Julian L; Phinichkusolchit N; Keeshan K; Blyth K; Olson MF
Dis Model Mech; 2024 May; 17(5):. PubMed ID: 38616733
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
